ImmunityBio
IBRX
IBRX
131 hedge funds and large institutions have $125M invested in ImmunityBio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
37% less capital invested
Capital invested by funds: $200M → $125M (-$74.4M)
45% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 31
Holders
131
Holding in Top 10
–
Calls
$1.99M
Puts
$2.08M
Top Buyers
| 1 | +$2.96M | |
| 2 | +$2.12M | |
| 3 | +$1.63M | |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.59M |
| 5 |
Renaissance Technologies
New York
|
+$1.49M |
Top Sellers
| 1 | -$18.2M | |
| 2 | -$2.24M | |
| 3 | -$1.85M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$861K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$708K |